Literature DB >> 20701443

Epigenomics and ovarian carcinoma.

Leonel Maldonado1, Mohammad Obaidul Hoque.   

Abstract

Ovarian cancer is the leading cause of death among gynecological cancers. It is now recognized that in addition to genetic alterations, epigenetic mechanisms, such as DNA methylation, histone modifications and nucleosome remodeling, play an important role in the development and progression of ovarian cancer by modulating chromatin structure, and gene and miRNA expression. Furthermore, epigenetic alterations have been recognized as useful tools for the development of novel biomarkers for diagnosis, prognosis, therapeutic prediction and monitoring of diseases. Moreover, new epigenetic therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been found to be a potential therapeutic option, especially when used in combination with other agents. Here we discuss current developments in ovarian carcinoma epigenome research, the importance of the ovarian carcinoma epigenome for development of diagnostic and prognostic biomarkers, and the current epigenetic therapies used in ovarian cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20701443      PMCID： PMC4441332          DOI： 10.2217/bmm.10.72

Source DB:  PubMed          Journal:  Biomark Med        ISSN： 1752-0363            Impact factor:   2.851


  263 in total

1.  Chromosomal instability and tumors promoted by DNA hypomethylation.

Authors:  Amir Eden; François Gaudet; Alpana Waghmare; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

Review 2.  Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes.

Authors:  M Esteller
Journal:  Eur J Cancer       Date:  2000-12       Impact factor: 9.162

Review 3.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  Silencing of the UCHL1 gene in human colorectal and ovarian cancers.

Authors:  Eriko Okochi-Takada; Kazuyuki Nakazawa; Mika Wakabayashi; Akiko Mori; Shizue Ichimura; Toshiharu Yasugi; Toshikazu Ushijima
Journal:  Int J Cancer       Date:  2006-09-15       Impact factor: 7.396

5.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

6.  A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.

Authors:  E Choan; Roanne Segal; Derek Jonker; Shawn Malone; Neil Reaume; Libni Eapen; Victor Gallant
Journal:  Urol Oncol       Date:  2005 Mar-Apr       Impact factor: 3.498

7.  p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.

Authors:  K Milde-Langosch; E Ocon; G Becker; T Löning
Journal:  Int J Cancer       Date:  1998-02-20       Impact factor: 7.396

8.  Epigenetic regulation of maspin expression in human ovarian carcinoma cells.

Authors:  Stephen L Rose; Matthew P Fitzgerald; Natalie O White; Michael J Hitchler; Bernard W Futscher; Koen De Geest; Frederick E Domann
Journal:  Gynecol Oncol       Date:  2006-02-07       Impact factor: 5.482

9.  Histone modifications silence the GATA transcription factor genes in ovarian cancer.

Authors:  C Caslini; C D Capo-chichi; I H Roland; E Nicolas; A T Yeung; X-X Xu
Journal:  Oncogene       Date:  2006-04-10       Impact factor: 9.867

10.  Characterization of protein-DNA association in vivo by chromatin immunoprecipitation.

Authors:  Laurent Kuras
Journal:  Methods Mol Biol       Date:  2004
View more
  20 in total

Review 1.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

Review 2.  The outstanding role of miR-132-3p in carcinogenesis of solid tumors.

Authors:  Milad Rafat; Mahta Moraghebi; Masoumeh Afsa; Kianoosh Malekzadeh
Journal:  Hum Cell       Date:  2021-05-17       Impact factor: 4.174

3.  microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs.

Authors:  Eric J Devor; Adriann M Hovey; Michael J Goodheart; Shyam Ramachandran; Kimberly K Leslie
Journal:  Oncol Rep       Date:  2011-07-01       Impact factor: 3.906

4.  MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.

Authors:  Xin Fu; Yanfen Cui; Shaobin Yang; Yue Xu; Zicheng Zhang
Journal:  Tumour Biol       Date:  2015-12-02

5.  Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population.

Authors:  Priscilla Brebi; Leonel Maldonado; Maartje G Noordhuis; Carmen Ili; Pamela Leal; Patricia Garcia; Mariana Brait; Judit Ribas; Christina Michailidi; Jimena Perez; Ethan Soudry; Oscar Tapia; Pablo Guzman; Sergio Muñoz; Leander Van Neste; Wim Van Criekinge; Rafael Irizarry; David Sidransky; Juan C Roa; Rafael Guerrero-Preston
Journal:  Epigenetics       Date:  2013-11-15       Impact factor: 4.528

6.  miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells.

Authors:  Hang Tian; Lei Hou; Yu-Mei Xiong; Jun-Xiang Huang; Wen-Hua Zhang; Yong-Ying Pan; Xing-Rong Song
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

7.  An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.

Authors:  Leonel Maldonado; Mariana Brait; Christina Michailidi; Enrico Munari; Tina Driscoll; Luciana Schultz; Trinity Bivalacqua; Mark Schoenberg; David Sidransky; George J Netto; Mohammad Obaidul Hoque
Journal:  Oncotarget       Date:  2014-07-30

Review 8.  Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice.

Authors:  Anliang Dong; Yan Lu; Bingjian Lu
Journal:  J Cancer       Date:  2016-07-05       Impact factor: 4.207

9.  Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues.

Authors:  Yifeng Gu; Peifang Yang; Qing Shao; Xia Liu; Sheng Xia; Miaomiao Zhang; Huaxi Xu; Qixiang Shao
Journal:  Oncol Lett       Date:  2012-12-03       Impact factor: 2.967

10.  Association of promoter methylation of VGF and PGP9.5 with ovarian cancer progression.

Authors:  Mariana Brait; Leonel Maldonado; Maartje G Noordhuis; Maartje Noordhuis; Shahnaz Begum; Myriam Loyo; Maria Luana Poeta; Alvaro Barbosa; Vito M Fazio; Roberto Angioli; Carla Rabitti; Luigi Marchionni; Pauline de Graeff; Ate G J van der Zee; G Bea A Wisman; David Sidransky; Mohammad O Hoque
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.